%0 Journal Article %T BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors %+ Tel Aviv University (TAU) %+ Universität Zürich [Zürich] = University of Zurich (UZH) %+ Zurich Basel Plant Science Center %+ Universität zu Lübeck = University of Lübeck [Lübeck] %+ Institut National de l'Environnement Industriel et des Risques (INERIS) %+ Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX) %+ Institute of Pathology %+ Brustzentrum Kantonsspital St. Gallen %A Ali, Omar Hasan %A Bomze, David %A Ring, Sandra S. %A Berner, Fiamma %A Fassler, Mirjam %A Diem, Stefan %A Abdou, Marie-Therese %A Hammers, Christoph %A Emtenani, Shirin %A Braun, Anne %A Cozzio, Antonio %A Mani, Bernhard %A Jochum, Wolfram %A Schmidt, Enno %A Zillikens, Detlef %A Sadik, Christian D. %A Flatz, Lukas %< avec comité de lecture %@ 0190-9622 %J Journal of The American Academy of Dermatology %I Elsevier %V 82 %N 4 %P 854-861 %8 2020 %D 2020 %R 10.1016/j.jaad.2019.08.045 %K anti-PD1 %K autoantibodies %K immune checkpoint inhibitors %K immune-related adverse events %K non-small cell lung cancer %K skin rash %Z Life Sciences [q-bio]Journal articles %X Background: Anti-programmed cell death protein 1 (PD1)/programmed death-ligand 1(PD-L1) therapy frequently entails immune-related adverse events (irAEs), and biomarkers to predict irAEs are lacking. Although checkpoint inhibitors have been found to reinvigorate T cells, the relevance of autoantibodies remains elusive. Objective: Our aim was to explore whether IgG autoantibodies directed against coexpressed antigens by tumor tissue and healthy skin correlate with skin irAEs and therapy outcome. Methods: We measured skin-specific IgG via enzyme-linked immunosorbent assay in patients with non-small cell lung cancer (NSCLC) who received anti-PD1/PD-L1 treatment between July 2015 and September 2017 at the Kantonsspital St. Gallen. Sera were sampled at baseline and during therapy after 8 weeks. Results: Analysis of publicly available tumor expression data revealed that NSCLC and skin coexpress BP180, BP230, and type VII collagen. A skin irAE developed in 16 of 40 recruited patients (40%). Only elevated anti-BP180 IgG at baseline significantly correlated with the development of skin irAEs (P = .04), therapy response (P = .01), and overall survival (P = .04). Limitations: The patients were recruited in a single tertiary care center. Conclusions: Our data suggest that the level of anti-BP180 IgG of NSCLC patients at baseline is associated with better therapy response and overall survival and with a higher probability to develop skin irAEs during anti-PD1/PD-L1 treatment. %G English %L hal-03548805 %U https://u-picardie.hal.science/hal-03548805 %~ INERIS %~ UNIV-PICARDIE %~ U-PICARDIE %~ PERITOX